Adimab LLC's VCs expect to be in the black starting next year thanks to the antibody company's three recent tech transfer deals, including one last week with Novo Nordisk A/S. Adimab hopes the deals will mark the start of a steady flow of dividend checks to its investors.

CEO Tillman Gerngross said Adimab's business development strategy from the start has been to deploy its yeast-based antibody discovery technology as widely as possible (see BioCentury, March 31, 2008).